HIV vaccine : Nice to see Results

While a fully preventive HIV vaccine is not yet approved, recent scientific advancements show very promising results in preclinical and early-phase trials. [1, 2, 3, 4]

Recent Vaccine & Immunology Progress

• Broadly Neutralizing Antibodies (bnAbs): Researchers at institutions like the La Jolla Institute for Immunology have developed vaccine candidates that prompt primate immune systems to produce rare bnAbs capable of bypassing HIV defenses, with human trials now underway. [1]
• T-Cell Boosting: Recent trials evaluating mosaic and conserved-region vaccines (such as HIVconsvX) demonstrate robust T-cell responses in participants, safely targeting vulnerable parts of the virus. [1]
• mRNA Approaches: Clinical trials using multi-component mRNA platforms are actively testing prime-boost strategies designed to trigger broad neutralizing antibody lineages. [1]

Major Breakthroughs in Long-Acting Prevention

• Lenacapavir Approval: The FDA and the World Health Organization approved and recommended twice-yearly injectable lenacapavir as a pre-exposure prophylaxis (PrEP) option. [1, 2]
• Efficacy: Clinical trials showed near 100% effectiveness in preventing new infections, offering a powerful long-acting alternative to daily oral PrEP pills. (Note: Lenacapavir is an antiviral drug preventing replication, not a traditional immune-training vaccine). [1, 2, 3]

HIV vaccine human trials moves on to next stage of testing

What is about classical vaccination approaches for HIV .

Classical vaccination approaches that have been successful in the control of various viral diseases by priming the adaptive immunity to recognize the viral envelope proteins have failed in the case of HIV-1. Some have stated that an HIV vaccine may not be possible without significant theoretical advances.  Identification of the Human Immunodeficiency Virus as the causative agent of AIDS (Acquired Immunodeficiency Syndrome) has been done long back. But till now a successful vaccine is still lacking and many efforts have gone in vain to stop the AIDS pandemic. A major success in this field of medical research has been the development of the highly active anti HIV treatment.   As of now this treatment is availabe to an increasing number of people worldwide. However, a safe and effective vaccine trial is still experimental which can  eradicate the HIV disease.

Why there is difficulty in making HIV vaccine?

Factors that  differ from the development of   HIV vaccine from other classic vaccines: 

• Classic vaccines mimic natural immunity against reinfection generally seen in individuals recovered from infection; there are almost no recovered AIDS patients. 
• Most vaccines protect against disease, not against infection; HIV infection may remain latent for long periods before causing AIDS. 
• Most effective vaccines are whole-killed or live-attenuated organisms; killed HIV-1 does not retain antigenicity and the use of a live retrovirus vaccine raises safety issues.

What is the recent development in HIV Vaccine?

The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study.

HIV Vaccine

What is the effect of new HIV vaccine in trials?

The new vaccine is protective in monkeys, and antibodies against HIV were generated in humans. it has to be tested and watched further whether the vaccine will protect against infection in real scenario.

READ ARTICLE FROM LANCET